Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer

Inhye Jeong, Sun Kyoung Kang, Woo Sun Kwon, Hyun Jeong Kim, Kyoo Hyun Kim, Hyun Myong Kim, Andre Lee, Suk Kyeong Lee, Thomas Bogenrieder, Hyuncheol Chung, SunYoung Rha

Research output: Contribution to journalArticle

Abstract

Several carcinomas including gastric cancer have been reported to contain Epstein-Barr virus (EBV) infection. EBV-associated gastric cancer (EBVaGC) is classified as one of four molecular subtypes of gastric cancer by The Cancer Genome Atlas (TCGA) group with increased immune-related signatures. Identification of EBV-dependent pathways with significant biological roles is needed for EBVaGC. To compare the biological changes between AGS gastric epithelial cells and EBV-infected AGS (AGS-EBV) cells, proliferation assay, CCK-8 assay, invasion assay, cell cycle analysis, RT-PCR, Western blot and ELISA were performed. BI836845, a humanized insulin-like growth factor (IGF) ligand-neutralizing antibody, was used for IGF-related signalling pathway inhibition. AGS-EBV cells showed slower proliferating rate and higher sensitivity to BI836845 compared to AGS cells. Moreover, invasiveness of AGS-EBV was increased than that of AGS, and BI836845 treatment significantly decreased the invasiveness of AGS-EBV. Although no apoptosis was detected, entry into the S phase of the cell cycle was delayed in BI836845-treated AGS-EBV cells. In conclusion, AGS-EBV cells seem to modulate their proliferation and invasion through the IGF signalling pathway. Inhibition of the IGF signalling pathway therefore could be a potential therapeutic strategy for EBVaGC.

Original languageEnglish
Pages (from-to)5899-5908
Number of pages10
JournalJournal of Cellular and Molecular Medicine
Volume22
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Somatomedins
Human Herpesvirus 4
Stomach Neoplasms
Cell Cycle
Sincalide
Epstein-Barr Virus Infections
Atlases
Neutralizing Antibodies
S Phase
Stomach
Western Blotting
Epithelial Cells
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Genome
Apoptosis
Ligands
Carcinoma
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cell Biology

Cite this

Jeong, Inhye ; Kang, Sun Kyoung ; Kwon, Woo Sun ; Kim, Hyun Jeong ; Kim, Kyoo Hyun ; Kim, Hyun Myong ; Lee, Andre ; Lee, Suk Kyeong ; Bogenrieder, Thomas ; Chung, Hyuncheol ; Rha, SunYoung. / Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. In: Journal of Cellular and Molecular Medicine. 2018 ; Vol. 22, No. 12. pp. 5899-5908.
@article{6f99651703c547f7a203709e0f77e357,
title = "Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer",
abstract = "Several carcinomas including gastric cancer have been reported to contain Epstein-Barr virus (EBV) infection. EBV-associated gastric cancer (EBVaGC) is classified as one of four molecular subtypes of gastric cancer by The Cancer Genome Atlas (TCGA) group with increased immune-related signatures. Identification of EBV-dependent pathways with significant biological roles is needed for EBVaGC. To compare the biological changes between AGS gastric epithelial cells and EBV-infected AGS (AGS-EBV) cells, proliferation assay, CCK-8 assay, invasion assay, cell cycle analysis, RT-PCR, Western blot and ELISA were performed. BI836845, a humanized insulin-like growth factor (IGF) ligand-neutralizing antibody, was used for IGF-related signalling pathway inhibition. AGS-EBV cells showed slower proliferating rate and higher sensitivity to BI836845 compared to AGS cells. Moreover, invasiveness of AGS-EBV was increased than that of AGS, and BI836845 treatment significantly decreased the invasiveness of AGS-EBV. Although no apoptosis was detected, entry into the S phase of the cell cycle was delayed in BI836845-treated AGS-EBV cells. In conclusion, AGS-EBV cells seem to modulate their proliferation and invasion through the IGF signalling pathway. Inhibition of the IGF signalling pathway therefore could be a potential therapeutic strategy for EBVaGC.",
author = "Inhye Jeong and Kang, {Sun Kyoung} and Kwon, {Woo Sun} and Kim, {Hyun Jeong} and Kim, {Kyoo Hyun} and Kim, {Hyun Myong} and Andre Lee and Lee, {Suk Kyeong} and Thomas Bogenrieder and Hyuncheol Chung and SunYoung Rha",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/jcmm.13859",
language = "English",
volume = "22",
pages = "5899--5908",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "12",

}

Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. / Jeong, Inhye; Kang, Sun Kyoung; Kwon, Woo Sun; Kim, Hyun Jeong; Kim, Kyoo Hyun; Kim, Hyun Myong; Lee, Andre; Lee, Suk Kyeong; Bogenrieder, Thomas; Chung, Hyuncheol; Rha, SunYoung.

In: Journal of Cellular and Molecular Medicine, Vol. 22, No. 12, 01.12.2018, p. 5899-5908.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer

AU - Jeong, Inhye

AU - Kang, Sun Kyoung

AU - Kwon, Woo Sun

AU - Kim, Hyun Jeong

AU - Kim, Kyoo Hyun

AU - Kim, Hyun Myong

AU - Lee, Andre

AU - Lee, Suk Kyeong

AU - Bogenrieder, Thomas

AU - Chung, Hyuncheol

AU - Rha, SunYoung

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Several carcinomas including gastric cancer have been reported to contain Epstein-Barr virus (EBV) infection. EBV-associated gastric cancer (EBVaGC) is classified as one of four molecular subtypes of gastric cancer by The Cancer Genome Atlas (TCGA) group with increased immune-related signatures. Identification of EBV-dependent pathways with significant biological roles is needed for EBVaGC. To compare the biological changes between AGS gastric epithelial cells and EBV-infected AGS (AGS-EBV) cells, proliferation assay, CCK-8 assay, invasion assay, cell cycle analysis, RT-PCR, Western blot and ELISA were performed. BI836845, a humanized insulin-like growth factor (IGF) ligand-neutralizing antibody, was used for IGF-related signalling pathway inhibition. AGS-EBV cells showed slower proliferating rate and higher sensitivity to BI836845 compared to AGS cells. Moreover, invasiveness of AGS-EBV was increased than that of AGS, and BI836845 treatment significantly decreased the invasiveness of AGS-EBV. Although no apoptosis was detected, entry into the S phase of the cell cycle was delayed in BI836845-treated AGS-EBV cells. In conclusion, AGS-EBV cells seem to modulate their proliferation and invasion through the IGF signalling pathway. Inhibition of the IGF signalling pathway therefore could be a potential therapeutic strategy for EBVaGC.

AB - Several carcinomas including gastric cancer have been reported to contain Epstein-Barr virus (EBV) infection. EBV-associated gastric cancer (EBVaGC) is classified as one of four molecular subtypes of gastric cancer by The Cancer Genome Atlas (TCGA) group with increased immune-related signatures. Identification of EBV-dependent pathways with significant biological roles is needed for EBVaGC. To compare the biological changes between AGS gastric epithelial cells and EBV-infected AGS (AGS-EBV) cells, proliferation assay, CCK-8 assay, invasion assay, cell cycle analysis, RT-PCR, Western blot and ELISA were performed. BI836845, a humanized insulin-like growth factor (IGF) ligand-neutralizing antibody, was used for IGF-related signalling pathway inhibition. AGS-EBV cells showed slower proliferating rate and higher sensitivity to BI836845 compared to AGS cells. Moreover, invasiveness of AGS-EBV was increased than that of AGS, and BI836845 treatment significantly decreased the invasiveness of AGS-EBV. Although no apoptosis was detected, entry into the S phase of the cell cycle was delayed in BI836845-treated AGS-EBV cells. In conclusion, AGS-EBV cells seem to modulate their proliferation and invasion through the IGF signalling pathway. Inhibition of the IGF signalling pathway therefore could be a potential therapeutic strategy for EBVaGC.

UR - http://www.scopus.com/inward/record.url?scp=85053715712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053715712&partnerID=8YFLogxK

U2 - 10.1111/jcmm.13859

DO - 10.1111/jcmm.13859

M3 - Article

VL - 22

SP - 5899

EP - 5908

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 12

ER -